The US Food and Drug Administration (FDA) issued an update on the progress in developing countermeasures to treat and prevent the novel coronavirus (COVID-19) and contagion live has published news that says there are at least 6 clinical trials underway evaluating Remedesivir.
Gilead Sciences, an American biotechnology company that researches, develops and commercializes drugs, says it has submitted a request to US FDA to rescind orphan drug designation granted for investigational antiviral for the treatment of COVID-19.
- Gilead says working to advance the development of Remdesivir as quickly as possible.
- Gilead Sciences says submitted request to US FDA to waive all benefits that accompany the orphan drug designation.
This will take time and what markets are looking for is an excuse to base, consolidate and move higher. However, COVID-19 may have only just got started and that is the fear. A catching falling knife strategy could be costly. Stimulus plans will only be so good as a bullish catalyst until the market digests the implications for Wall Street having just lost its biggest bid - the share buy-back bid.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.